Effects of central nervous system drugs on androgen, estrogen α, glucocorticoid, and thyroid receptors

• Published in: Chemico-biological interactions Vol. 363; p. 110030
• Main Authors: Kenda, Maša, Zore, Taja, Sollner Dolenc, Marija
• Format: Journal Article
• Language: English
• Published: Elsevier B.V 25.08.2022
• Subjects: Central nervous system drugs; Endocrine toxicity; Hormonal effects; Nuclear receptors; Reporter-gene assays; Reporter-gene assays; Endocrine toxicity; Central nervous system drugs; Nuclear receptors; Hormonal effects
• ISSN: 0009-2797; 1872-7786
• DOI: 10.1016/j.cbi.2022.110030

Some drugs that act on the central nervous system (CNS) are known to affect the endocrine system, although the mechanisms of endocrine toxicity are not well characterized to date. Such CNS drugs include antipsychotics, anticonvulsants, and antidepressants. In the present study, in-vitro firefly luciferase reporter-gene assays using the AR-EcoScreen assay using Chinese hamster ovary (CHO) cell line, hERα-HeLa9903, MDA-kb2, and GH3.TRE-Luc cell lines were used to determine the effects of nine CNS drugs on the androgen receptor, estrogen receptor α, glucocorticoid receptor, and thyroid hormone receptor, respectively. In the AR-EcoScreen assay using CHO cells, anti-androgenic activities were shown for carbamazepine (IC50, 167 μM), clonazepam (IC50, 26.7 μM), eslicarbazepine acetate (IC50, 375 μM), fluoxetine (at 25 μM), lorazepam (IC50, 16.4 μM), and sertraline (IC50, 8.7 μM). In the hERα-HeLa-9903 cells, estrogen receptor α agonistic activities were shown for fluoxetine, paroxetine, and sertraline (at 10 μM and 25 μM), and in the GH3.TRE-Luc cells, the same three CNS drugs showed antithyroid activities (IC50s, 11.6, 11.9, 2.7 μM, respectively). In the hERα-HeLa-9903 cells, estrogen receptor α antagonistic activities were shown for carbamazepine (IC50, 114.3 μM), clonazepam (IC50, 52.9 μM), and eslicarbazepine acetate (IC50, 376.6 μM). When the CNS drugs were tested in the MDA-kb2 cells, none of them showed any activities toward glucocorticoid receptors. Little to no effects were seen toward any of these nuclear receptors for paliperidone and risperidone. The increased signal in the estrogen receptor α agonism assay seen for fluoxetine and paroxetine was confirmed to be mediated through estrogen receptor α. Additionally, we examined the interference of these CNS drugs with the firefly luciferase enzyme. These data elucidate the potential for adverse endocrine effects for some of these CNS drugs, which should therefore contribute to informed choice when prescribing them. However, long-term exposure to therapeutic concentrations of CNS drugs that have activities on the endocrine system should be explored further also in vivo. •Some drugs that act on CNS are known to affect the endocrine system.•Reporter-gene assays were used to determine the effects of nine CNS drugs.•Of the four nuclear receptors studied, AR was the most affected.•Fluoxetine, paroxetine, and most notably sertraline modulate activity of TR.•Estrogenic effects of SSRIs may be associated with a reduction in hot flashes.